Jørgensen TS, Skougaard M, Hansen RL, et al. - In this population-based cohort study, researchers sought to explore the connection between fatigue with disease activity and drug survival in patients with psoriatic arthritis (PsA) receiving their first tumor necrosis factor inhibitor (TNFi). From 2006 to 2015, data on patient characteristics, disease activity, and drug survival were obtained from the DANBIO database for all patients with PsA. In total, 880 patients were eligible for analyses. Fatigue remains a dominating symptom after TNFi treatment, and is linked to higher baseline disease activity, pain, and HAQ scores; more comorbidities; and increased risk of TNFi treatment cessation in a cohort of Danish patients with PsA. The agreement between the American College of Rheumatology and visual analog scale fatigue responses is weak to moderate, indicating that there is heterogeneity between fatigue and joint inflammation.